SAMHD1 and chronic myelogenous leukemia, BCR-ABL1 positive: (3) PBMCs from CML patients showed lower SAMHD1 phosphorylation after PHA/IL-2 treatment for five days (p < 0.0001 for dasatinib; p < 0.01 for bosutinib).